

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

Ultra-LEAF(TM) Purified anti-mouse CD28

RRID:AB_11147170

Type: Antibody

Proper Citation

(BioLegend Cat# 102116, RRID:AB_11147170)

Antibody Information

URL: http://antibodyregistry.org/AB_11147170

Proper Citation: (BioLegend Cat# 102116, RRID:AB_11147170)

Target Antigen: CD28

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC, IP, IHC-F, Costim, Block

Antibody Name: Ultra-LEAF(TM) Purified anti-mouse CD28

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: Clone 37.51

Antibody ID: AB_11147170

Vendor: BioLegend

Catalog Number: 102116

Alternative Catalog Numbers: 102121, 102132, 102131, 102122, 102115

Record Creation Time: 20260526T044338+0000

Record Last Update: 20260526T044338+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-mouse CD28.

No alerts have been found for Ultra-LEAF(TM) Purified anti-mouse CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 97 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wang H, et al. (2026) Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity. Cancer research communications, 6(3), 500.

Chemla Y, et al. (2026) HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. Cell, 189(1), 233.

Arumugam P, et al. (2026) Mitochondrial transfer to granulocytic myeloid-derived suppressor cells augments immunosuppressive activity. Cell reports, 45(3), 117057.

Li Y, et al. (2026) CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses. Molecular therapy. Oncology, 34(2), 201230.

Yao B, et al. (2026) Divergent tumor immunity determined by bacteria-cancer cell engagement. Cell, 189(6), 1748.

Chen S, et al. (2026) 16-h fasting optimizes cancer immunotherapy in mice and humans. Cell metabolism, 38(5), 944.

Mochizuki-Ono C, et al. (2026) PLA2G12A-driven extracellular vesicle-lipid signaling amplifies pathogenic T cell responses in inflammatory diseases. Cell reports, 45(6), 117391.

Li X, et al. (2026) The TCR-SUB1-DOCK2 axis promotes autoimmunity by driving pathogenic CD4+ T cell tissue infiltration. Immunity, 59(1), 98.

Tripathi A, et al. (2026) Protocol for intranuclear Nrf2 detection in activated mouse, human, and Jurkat T cells by spectral flow cytometry. STAR protocols, 7(1), 104360.

Kureshi CTS, et al. (2026) Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer cell, 44(7), 1381.

Liu Z, et al. (2026) Activation-gated, T cell-restricted silencing of Dapk1 enhances Bacille Calmette-Guérin-elicited protective CD4+ memory. iScience, 29(5), 115593.

Zhang P, et al. (2026) Sympathetic-epithelial crosstalk governs tissue-resident memory T cell immunosurveillance in the skin. *Cell*, 189(5), 1323.

De la Torre Medina J, et al. (2026) Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway. *Molecular cancer therapeutics*, 25(6), 957.

Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. *Cell reports*, 45(1), 116796.

Pang J, et al. (2026) Law-NQO1 redox boosts the pentose phosphate pathway to confer stem-like properties and antitumor durability in effector CD8⁺ T cells. *Cell chemical biology*, 33(3), 321.

Dong P, et al. (2026) Enhanced HIF-1 α cooperation by a human ROR γ t mutant potentiates Th17 pathogenicity. *Cell reports*, 45(4), 117123.

Scaglione M, et al. (2026) Metabolic and transcriptional plasticity supports CD8⁺ T cell resilience and anti-tumor immunity under nutrient stress. *Immunity*, 59(5), 1344.

Yang S, et al. (2026) Oat- β -glucan potentiates anti-PD-1 efficacy through *Faecalibacterium prausnitzii*-derived butyrate and indole-3-propionic acid. *Cell host & microbe*, 34(7), 1333.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Brown ME, et al. (2025) Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function. *Diabetologia*, 68(2), 397.